1,721,057 research outputs found
Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
No full textMetastatic non-small cell lung cancer:ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Full text linkCorrigendum to “Adrenocortical carcinomas and malignant phaeochromocytomas: ESMO-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up": [Annals of Oncology volume 31 (2020) 1476-1490]
No full textThe authors regret that the legend to Fig. 4 of this publication was given incorrectly. The correction is as follows: For “CVD, cyclophosphamide, vincristine, doxorubicin” read “CVD, cyclophosphamide, vincristine, dacarbazine”. The authors would like to apologise for any inconvenience caused
Renal cell carcinoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up
Full text linkN
Early and locally advanced non-small-cell lung cancer: an update of the ESMO Clinical Practice Guidelines focusing on diagnosis, staging, systemic and local therapy.
No full textAdrenocortical carcinomas and malignant phaeochromocytomas: ESMO–EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up†
No full textCorrigendum to ‘Salivary gland cancer: ESMO-European Reference Network on Rare Adult Solid Cancers (EURACAN) Clinical Practice Guideline for diagnosis, treatment and follow-up': [ESMO Open 7(6):100602, December 2022]
No full textThe authors regret that there were errors in the text and published figures. The authors would like to apologise for any inconvenience caused. The corrections are as follows: On page 3, in Figure 1, an option is added after “cT1-T2, N0”: • High gradecThis option then connects with the box containing “CT of the chest FDG–PET–CT [III, A]”. On page 3, in Figure 1 and the figure footnote, a new footnote ‘b’ is added to the following boxes: • cT3-T4, N0 or AdCC any stageb• cT1-T2, N0bb bFDG–PET–CT is recommended for treatment planning in lymph node-positive or high-grade SGC; otherwise, CT of the chest can suffice.On page 3, in Figure 1 and the figure footnote, a new footnote ‘c’ is added to the following box: • High gradecc cDefinition of high-grade tumours is described in Section 1 of the Supplementary Material, available at https://doi.org/10.1016/j.esmoop.2022.100602. On page 3: • FDG–PET–CT is recommended in high-grade SGC for the detection of distant metastases [III, A].is replaced with: • FDG–PET–CT is recommended in high-grade or lymph-node positive SGC for the detection of distant metastases [III, A]. On page 5, in Figure 2: • No high-risk factors: RT to primary [IV, A]is replaced with: • High-risk factors: RT to primary [IV, A]On page 5, in Figure 2: • RT to neckis replaced with: • RT to level I-V for pN+ [IV, A]and an arrow is added between the box containing “END II-IV (I and V on indication) [IV, B] and the box containing “pN0”. On page 5, in Figure 2: • pN+ and no high-risk factors: RT to level I-V [IV, A]is replaced with an arrow to the box containing “RT to level I-V for pN+ [IV, A]”. On page 6, in Figure 3, an additional option is added following “Open approach [IV, A]” and “Selected transoral/endoscopic/robotic [V, A]”: • High-risk factors: RT to primary [IV, A] On page 8, in Figure 4, an additional option is added following “Resection of submandibular gland and level Ib [IV, B]”: • pN+with arrows connecting to “Comprehensive ND I-V including the primary [IV, A]” and “RT to level I-V [IV, A]”. On page 8, in Figure 4: • pN0: No additional treatmentis replaced with: • pN0with an arrow connecting to: • High-risk factors: RT to primary [IV, A] On page 9, before the recommendations of “Surgical management of the primary: submandibular gland cancer” the following text is added: • Surgical management of the primary: minor SGC and cancer of the sublingual gland o Depending on the anatomical site of origin, a classical open approach [IV, A] or endoscopic, transoral or combined transoral-endoscopic resection [V, A] are recommended in selected patients, with the aim of achieving free margins. On page 10: • In case of R/M disease, systemic treatment is challenging but can be urgent, depending on tumour subtype and behaviour. For all types of SGC with distant metastases (71% of patients will present or develop R/M disease), median OS is 15 months and 1-, 3- and 5-year OS rates are 54.5%, 28.4% and 14.8%, respectively.is replaced with: • In case of R/M disease, systemic treatment is challenging but can be urgent, depending on tumour subtype and behaviour. For all types of SGC with distant metastases (up to 60% of patients will present or develop R/M disease), median OS is 15 months and 1-, 3- and 5-year OS rates are 54.5%, 28.4% and 14.8%, respectively
Care of the adult cancer patient at the end of life: ESMO Clinical Practice Guidelines
Full text link• This ESMO Clinical Practice Guideline provides key recommendations for end-of-life care for patients with advanced cancer. • It details care that is focused on comfort, quality of life and approaching death of patients with advanced cancer. • All recommendations were compiled by a multidisciplinary group of experts. • Recommendations are based on available scientific data and the authors’ collective expert opinion.G. B. Crawford, T. Dzier, zanowski, K. Hauser, P. Larkin, A. I. Luque-Blanco, I. Murphy, C. M. Puchalski, C. I. Ripamonti, on behalf of the ESMO Guidelines Committe
Salivary gland cancer: ESMO-European Reference Network on Rare Adult Solid Cancers (EURACAN) Clinical Practice Guideline for diagnosis, treatment and follow-up
Full text linkThis ESMO–EURACAN Clinical Practice Guideline provides key recommendations for managing salivary gland cancer. • The guideline covers clinical and pathological diagnosis, staging and risk assessment, treatment and follow-up. • Treatment algorithms for parotid, submandibular, sublingual and minor salivary gland cancer are provided. • The author group encompasses a multidisciplinary group of experts from different institutions and countries in Europe. • Recommendations are based on available scientific data and the authors’ collective expert opinion
Cutaneous melanoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
No full text- …
